Home|Best-Bschool-in-india-2018

DSIJ Mindshare

Multibagger FMCG stock with no dark spots; it checks all the boxes for solid earnings and hits an all-time high! Multibagger FMCG stock with no dark spots; it checks all the boxes for solid earnings and hits an all-time high!

Multibagger FMCG stock with no dark spots; it checks all the boxes for solid earnings and hits an all-time high!

The stock showing remarkable growth over the past year, surging by an impressive 112.55 per cent. Furthermore, its three-year return of 207.71 per cent and the maximum return of 957.45 per cent highlights the enormous potential and value it has generated for its shareholders.

Prajwal Wakhare 0 3802 Article rating: 4.4
Read more
Don't miss action in this micro-cap multibagger which is on verge of multi-year breakout Don't miss action in this micro-cap multibagger which is on verge of multi-year breakout

Don't miss action in this micro-cap multibagger which is on verge of multi-year breakout

ITD is a low price-to-earnings stock, with a PE of 13.8, compared to the industry PE of 48.3. This means that ITD is trading at a significant discount to its peer

Prajwal Wakhare 0 4385 Article rating: 4.1

The company's financial performance for the quarter ended November 7, 2023, was strong, with both revenue and profit increasing from the previous quarter. Total revenue from operations increased by 11.85 per cent to Rs. 39.80 crores, while net profit increased by 10.26 per cent to Rs. 5.65 crores. The company's stock price also reflected its strong performance, reaching a new 52-week high of Rs. 344.00 on November 7, 2023, on high volume.

Read more
5,000 per cent returns: Vijay Kedia's and Mukul Agarwal's small-cap pharmaceutical stock reported stellar performance; check if you hold it! 5,000 per cent returns: Vijay Kedia's and Mukul Agarwal's small-cap pharmaceutical stock reported stellar performance; check if you hold it!

5,000 per cent returns: Vijay Kedia's and Mukul Agarwal's small-cap pharmaceutical stock reported stellar performance; check if you hold it!

Neuland Laboratories' strong Q2FY24 performance was driven by the CMS vertical, which grew 43% YoY.

Prajwal Wakhare 1 18870 Article rating: 4.2

Neuland Laboratories, in an impressive Q2FY24 performance, has seen a remarkable 43 per cent year-on-year growth in its Contract Manufacturing Services (CMS) vertical, propelling the company's EBITDA margin to a substantial 33.4 per cent, a remarkable 980 basis points increase YoY. This remarkable progress can be attributed to both higher revenues and a strategic shift towards high-margin business

Read more
RSS
First6970717273757778
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual

View Registration Certificate

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual

View Registration Certificate

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP
BASL Membership ID: 1346

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Condition | Privacy Statement | WhiteList